Prevalence of cerebrotendinous xanthomatosis among patients diagnosed with early-onset idiopathic bilateral cataracts: final analysis.


Journal

Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
ISSN: 1528-3933
Titre abrégé: J AAPOS
Pays: United States
ID NLM: 9710011

Informations de publication

Date de publication:
08 2023
Historique:
received: 07 03 2023
accepted: 17 04 2023
medline: 11 9 2023
pubmed: 16 6 2023
entrez: 15 6 2023
Statut: ppublish

Résumé

Cerebrotendinous xanthomatosis (CTX) is a rare, autosomal recessive bile acid synthesis disorder caused by pathologic variants in CYP27A1, a gene involved in bile acid synthesis. Impaired function in this gene leads to accumulation of plasma cholestanol (PC) in various tissues, often in early childhood, resulting in such clinical signs as infantile diarrhea, early-onset bilateral cataracts, and neurological deterioration. The current study aimed to identify cases of CTX in a population of patients with a greater CTX prevalence than the general population, to facilitate early diagnosis. Patients diagnosed with early-onset, apparently idiopathic, bilateral cataracts between the ages of 2 and 21 years were enrolled. Genetic testing of patients with elevated PC and urinary bile alcohol (UBA) levels was used to confirm CTX diagnosis and determine CTX prevalence. Of 426 patients who completed the study, 26 met genetic testing criteria (PC ≥ 0.4 mg/dL and positive UBA test), and 4 were confirmed to have CTX. Prevalence was found to be 0.9% in enrolled patients, and 15.4% in patients who met the criteria for genetic testing.

Identifiants

pubmed: 37321343
pii: S1091-8531(23)00119-2
doi: 10.1016/j.jaapos.2023.04.013
pii:
doi:

Substances chimiques

Cholestanol 8M308U816E
Bile Acids and Salts 0

Types de publication

Case Reports Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

208-211

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Sharon F Freedman (SF)

Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina. Electronic address: sharon.freedman@duke.edu.

Monte A Del Monte (MA)

Department of Ophthalmology and Visual Sciences, University of Michigan, Kellogg Eye Center, Ann Arbor, Michigan.

Ulysses Diva (U)

Travere Therapeutics Inc, San Diego, California.

Sean P Donahue (SP)

Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.

Arlene V Drack (AV)

Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals & Clinics, Iowa City, Iowa.

Rana Dutta (R)

Travere Therapeutics Inc, San Diego, California.

Simon S M Fung (SSM)

University of California, Los Angeles, California.

Michael Imperiale (M)

Travere Therapeutics Inc, San Diego, California.

Catherine O Jordan (CO)

Nationwide Children's Hospital, Columbus, Ohio.

Phoebe D Lenhart (PD)

Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia.

Maria E Lim (ME)

Dean McGee Eye Institute, University of Oklahoma, Oklahoma City, Oklahoma.

Emily A McCourt (EA)

Department of Ophthalmology, University of Colorado School of Medicine, Children's Hospital of Colorado, Anschutz Medical Campus, Aurora, Colorado.

Bharti R Nihalani (BR)

Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Tarlan Sabahi (T)

Travere Therapeutics Inc, San Diego, California.

Erin D Stahl (ED)

Department of Ophthalmology, Children's Mercy Kansas City, UMKC School of Medicine, Kansas City, Missouri.

Virginia A Miraldi Utz (VA)

Abrahamson Pediatric Eye Institute, Cincinnati Children's Hospital, Cincinnati, Ohio.

M Edward Wilson (ME)

Department of Ophthalmology and Pediatrics, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina.

Kimberly G Yen (KG)

Division of Ophthalmology, Department of Surgery, Texas Children's Hospital/Baylor College of Medicine, Houston, Texas.

Deborah K VanderVeen (DK)

Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH